Glenn Coleman - 30 Sep 2026 Form 4 Insider Report for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)

Reporting relationship: EVP & Chief Financial Officer
Issuer ticker: CRL
Reported as of: 30 Sep 2026
Net transaction value: +$2,974
SEC form: 4
Accepted by SEC: 02 Oct 2026, 16:27:48 UTC
Prior SEC filing: 02 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Glenn Coleman

Key filing fact

Glenn Coleman filed Form 4 for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) on 02 Oct 2026.

Key facts

This page summarizes Glenn Coleman's Form 4 filing for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Oct 2026, 16:27.

Change

Previous filing in this sequence was filed on 02 Jun 2026.
Current net transaction value: +$2,974.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001434369 Primary reporting owner

Coleman Glenn

Relationship: EVP & Chief Financial Officer
Address: C/O CHARLES RIVER LABORATORIES, 251 BALLARDVALE ST, WILMINGTON
Signature: /s/ Glenn Coleman
Signature date: 02 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRL transaction

Common Stock

Purchase

Transaction value: $2,974
Shares: +10
Change %: +0.04%
Price: $297.43
Shares after: 27,762
Date: 30 Sep 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares were acquired pursuant to the Company's Employee Stock Purchase Plan at the fair market value of the Company's common stock on the purchase date. The Reporting Person elected to participate in the Plan during an open trading window prior to the commencement of the quarterly purchase period.